Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan

Detalles Bibliográficos
Autores principales: Hashimoto, Takanao, Murayama, Anju, Mamada, Hanano, Saito, Hiroaki, Tanimoto, Tetsuya, Ozaki, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610564/
https://www.ncbi.nlm.nih.gov/pubmed/34826620
http://dx.doi.org/10.1016/j.cmi.2021.11.019
_version_ 1784603123562577920
author Hashimoto, Takanao
Murayama, Anju
Mamada, Hanano
Saito, Hiroaki
Tanimoto, Tetsuya
Ozaki, Akihiko
author_facet Hashimoto, Takanao
Murayama, Anju
Mamada, Hanano
Saito, Hiroaki
Tanimoto, Tetsuya
Ozaki, Akihiko
author_sort Hashimoto, Takanao
collection PubMed
description
format Online
Article
Text
id pubmed-8610564
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-86105642021-11-24 Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan Hashimoto, Takanao Murayama, Anju Mamada, Hanano Saito, Hiroaki Tanimoto, Tetsuya Ozaki, Akihiko Clin Microbiol Infect Letter to the Editor European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-03 2021-11-24 /pmc/articles/PMC8610564/ /pubmed/34826620 http://dx.doi.org/10.1016/j.cmi.2021.11.019 Text en © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Hashimoto, Takanao
Murayama, Anju
Mamada, Hanano
Saito, Hiroaki
Tanimoto, Tetsuya
Ozaki, Akihiko
Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
title Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
title_full Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
title_fullStr Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
title_full_unstemmed Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
title_short Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
title_sort evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in japan
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610564/
https://www.ncbi.nlm.nih.gov/pubmed/34826620
http://dx.doi.org/10.1016/j.cmi.2021.11.019
work_keys_str_mv AT hashimototakanao evaluationoffinancialconflictsofinterestanddrugstatementsinthecoronavirusdisease2019clinicalpracticeguidelineinjapan
AT murayamaanju evaluationoffinancialconflictsofinterestanddrugstatementsinthecoronavirusdisease2019clinicalpracticeguidelineinjapan
AT mamadahanano evaluationoffinancialconflictsofinterestanddrugstatementsinthecoronavirusdisease2019clinicalpracticeguidelineinjapan
AT saitohiroaki evaluationoffinancialconflictsofinterestanddrugstatementsinthecoronavirusdisease2019clinicalpracticeguidelineinjapan
AT tanimototetsuya evaluationoffinancialconflictsofinterestanddrugstatementsinthecoronavirusdisease2019clinicalpracticeguidelineinjapan
AT ozakiakihiko evaluationoffinancialconflictsofinterestanddrugstatementsinthecoronavirusdisease2019clinicalpracticeguidelineinjapan

Ejemplares similares